Christine P. Bump

Christine P. Bump is an insightful regulatory attorney with more than 15 years of experience developing and implementing FDA strategies for cutting-edge technology. She focuses on regulatory issues relating to devices, diagnostics, genetics and genomics, digital health, wellness, and advertising and promotion. Christine counsels laboratories, start-ups, and large corporations, and advises clients with an awareness and understanding of their business and strategic goals. She has prepared clinical trial and customer user agreements for laboratory and wellness products, with emphasis on patient and data privacy.

Christine has also developed regulatory strategies for new technologies related to IVF and pre-implantation selection, and served as dedicated counsel to a fertility clinic. Her policy experience includes serving as a regulatory counsel for a national coalition of diagnostic companies. She has prepared unified comments on behalf of a coalition to FDA and Congress, and prepared lobbyists for meetings on Capitol Hill regarding alternatives to existing and proposed regulations.

• Food and Drug Law

District of Columbia

District of Columbia Bar

Since 2006

Georgia

Since 2004

Vice President

Goldbug Strategies LLC

2015 - 2019

Senior Associate

Goodwin Procter LLP

2009 - 2014

Associate

Hyman, Phelps & McNamara, P.C.

2004 - 2009

Emory University School of Law

J.D. | Law

2001 - 2004

Emory University

M.P.H | Health Policy and Management

2000 - 2004

Sweet Briar College

B.A. | Government

1996 - 2000

Honors: Honors Degree with High Honors; summa cum laude; Phi Beta Kappa

Rising Star

SuperLawyers

2013

Named a Rising Star in Food & Drug Law in Washington, DC

Dean's Public Service Award

Emory University School of Law

2004

Phi Beta Kappa

Sweet Briar College

2000

Presidential Medal

Sweet Briar College

2000

Food & Drug Law Institute

Member

2020 - Current

Women Owned Law

Member

2020 - Current

District of Columbia Bar

Member

2006 - Current

State Bar of Georgia

Member

2004 - Current

Food & Drug Law Institute

Editorial Advisory Board Member, Food and Drug Law Journal

2021 - 2023

Food & Drug Law Institute

Member

2004 - 2014

Food & Drug Law Institute

Editorial Advisory Board Member, Food and Drug Law Journal

2010 - 2013

"In Vitro Diagnostics Submissions and Compliance," in Fundamentals of U.S. Regulatory Affairs, Sixth Edition

Regulatory Affairs Professional Society

2009

"Environmental Health and Protection," in Law And Public Health Practice, Second Edition Edition

Oxford University Press

2007

"Clinical Trials Disclosure Requirements: Too Much of a Good Thing?"

RA Focus

January, 2006

"Courts Scrutinize FDA 'Disgorgement' Demands"

Washington Legal Foundation Legal Backgrounder

November, 2005

"Qualified Health Claims: Creatures of Case Law"

FDLI Update

November, 2005

"New Case Raises Doubts on FDA's Autority to Obtain Restitution and Disgorgement"

FDLI Update

May, 2005

"Close But No Cigar: The WHO Framework Convenvention's Futile Ban on Tobacco Advertising"

Emory International Law Review

2003

"Environmental Health and Protection," in Law And Public Health Practice, First Edition

Oxford University Press

2002

"Dissecting the VALID Act", Diagnostic Coverage & Reimbursement Conference, Chicago, IL

July 19, 2023

Q1 Productions

"Telemedicine and Remote Patient Monitoring: Public Health Emergency Next Steps & Associated Costs", Medical Device Coverage & Reimbursement Conference, Chicago, IL

July 18, 2023

Q1 Productions

"Dissecting the VALID Act", Diagnostic Coverage & Reimbursement Conference, Boston, MA

December 8, 2022

Q1 Productions

Moderator, “Preparing for the Next Public Health Crisis: Implementing a Culture-Centered Approach to Collaborative Communication Efforts by the FDA and CDC", The Interconnected Regulatory Landscape: Exploring FDA’s Relationship with Other Domestic Regulators, Virtual

November 3, 2022

Food and Drug Law Journal

"What Post-Marketing Issues Should I Be Considering?", Fundamentals of Digital Health Regulation: Successfully Navigating Your Product Through FDA

November 9, 2021

Food and Drug Law Institute

"Digital Health: Enforcement, Regulations, and Risks", FDLI Enforcement, Litigation, and Compliance Conference, Virtual

December 16, 2020

Food and Drug Law Institute

"Legal and Industry Perspectives of FDA's Regulation of Medical Devices", Medical Electronics Conference, Minneapolis, Minnesota

May 2007

Surface Mount Technology Association

"IVDMIAs: Is FDA Changing How Laboratories Operate?", Clinical Device Group E-Conference, Virtual

June 2007

Clinical Device Group

"Premarket Notification, 510(k)", Introduction to Medical Device Law and Regulation, Washington, DC

November 2010

Food & Drug Law Institute

"Presenting Risk Information in Promotional Materials & Good Reprint Practices", Advertising and Promotion of Medical Devices in an Age of DTC and Social Media Marketing, Washington, DC

November 2011

AdvaMed